We are interested in studying TGF b signaling pathways. In C elegans , a type II receptor,
daf-4 , is a common mediator of two distinct TGF b signaling pathways, the Dauer branch, and the Small branch. The Dauer branch mutants are Dauer-constitutive as well as Egg-laying defective, while the Small branch mutants have markedly reduced body size, approximately 50% that of the wild type, as well as defects in the male tail. Each of these pathways uses distinct Smads, the TGF b signaling molecules. We are characterizing the developmental consequences of mutations in these pathways. First, we are studying the egg-laying defective genes that may function with the Dauer branch. Previous studies have shown that two egg-laying genes,
egl-4 and
egl-32 , may be implicated in TGF b signaling by their suppression by
daf-3 , an antagonistic Smad of the Dauer branch which also suppresses the egg-laying phenotype of other upstream members of the Dauer pathway. We attempted to find other members of this pathway by testing other egg-laying mutants with similar pharmacological properties to
egl-4 and
egl-32 for suppression by
daf-3 . We've also mapped
egl-32 using chromosomal deficiencies and are in the process of cloning the gene. There are no known TGF b components in the area to which we've mapped
egl-32 , which means we are probably dealing with a new component of the pathway. Second, we are beginning to address the question of why Small mutants have reduced body size. As a first step, we've constructed growth curves of N2 and all known TGF b components of the Small pathway, showing that they have a postembronic growth defect leading to their reduced body size. We've also measured cell sizes to determine whether only some or all cells are smaller. Third, we have characterized a
sma-3 allelic series. These experiments show that
sma-3 is not an essential gene, acts specifically in the Small but not the Dauer branch, and that other Smads do not function in the absence of SMA-3.